Peptide Therapy and Payment Processing in 2026: Where Clinics Stand After FDA's Category Changes
FDA moved several peptides off its 503A Category 2 list in April 2026, according to legal and trade reporting. That changed less than some marketing suggests, and it didn't change what a processor needs to see from a peptide clinic.
A clinic that prescribes peptides through a licensed pharmacy faces the same underwriting questions as other prescription telehealth, with a few more about the products. A seller of research-use-only peptides starts from a far weaker position. FDA's reported April 2026 removal of BPC-157 and other peptides from 503A Category 2 doesn't, by itself, make any of them eligible for compounding, according to legal and trade reporting.
503A Category 2 is one of the categories FDA places bulk drug substances in after they are nominated for compounding under section 503A of the FD&C Act; Category 1 substances fall under an interim FDA policy. According to legal and trade reporting in 2026, removal from Category 2 doesn't by itself make a substance eligible for compounding.
What changed for peptides in 2026, as reported
As of November 2026, based on reporting by Goodwin, Frier Levitt and Pharmacy Times (April to June 2026). We haven't confirmed what followed FDA's July 2026 advisory committee meeting.
The reported sequence runs like this:
- February 2026. HHS Secretary Kennedy said, according to the reporting, that about 14 of the 19 peptides in Category 2 would move back to Category 1. That was a statement of intent, not a rule.
- April 2026. FDA removed BPC-157 and several other peptides from 503A Category 2 after their nominations were withdrawn, according to the reporting.
- July 23–24, 2026. FDA scheduled a Pharmacy Compounding Advisory Committee meeting, per the same reporting. Its outcome isn't confirmed in our research.
Every statement here about FDA and HHS comes from that secondary reporting. None of it is our characterization of any peptide's status.
What removal from Category 2 does and doesn't mean
As reported, it takes a substance off one list without putting it on another. Removal from Category 2 doesn't, by itself, make a substance eligible for compounding, and it doesn't bring the substance under FDA's interim Category 1 policy. In our reading, a withdrawn nomination ends that nomination; it isn't a decision in the substance's favor.
That is a narrower change than some peptide marketing describes. A site that tells patients a peptide is now "FDA approved," or that FDA "cleared" it in 2026, is claiming more than FDA's reported actions say, and an underwriter reading the site will notice.
The underlying framework is section 503A itself: compounding by a state-licensed pharmacy or physician, based on a valid prescription for an identified patient, with limits that include not compounding regularly or in inordinate amounts what are essentially copies of commercially available drugs. How that differs from FDA-registered outsourcing facilities under section 503B is in 503A vs 503B pharmacies for telehealth merchants.
This post makes no claim about whether any peptide may be compounded, prescribed or sold. That is a question for regulatory counsel and the pharmacy, and the answer can change with FDA's next action.
Why processors treat peptide sellers as their own question
Because several separate risks meet in one product line, in our reading:
- Prescription sales. If the business sells prescription products non-face-to-face, Visa treats that (MCC 5122 or 5912) as high-integrity risk, with registration duties for the acquirer under Visa §1.9.5.1.
- Certification. LegitScript describes its certification as "a necessary part of the approval process" for card-not-present transactions with Visa and Mastercard, for the businesses in its scope. Its FAQ lists research-use-only chemical businesses, including peptides, among those generally not eligible.
- Status in motion. A product list whose regulatory standing is still being reported on is a product list that can change under a patient's prepaid plan.
- Network exposure. Among the grounds on which Visa §1.9.1.4 allows a permanent prohibition is non-compliance with the Visa Integrity Risk Program, which includes "illegal or brand-damaging" transaction activity.
Three peptide business models, as an underwriter sees them
The same molecule can sit in very different businesses, and the business decides the file.
| Model | What the patient pays for | LegitScript, per its FAQ | What an underwriter will want |
|---|---|---|---|
| Telehealth clinic prescribing peptides, filled by a pharmacy | Visits or a membership; medication charged by the clinic or the pharmacy | Telemedicine providers are generally eligible | Prescriber licenses, the pharmacy and its 503A or 503B status, the product list, marketing |
| In-person clinic or med spa charging face to face | Treatments in the clinic | In-person-only clinics, and med spas without telemedicine prescribing or card-not-present prescription payments, are generally not eligible | Licenses, what is administered and where it is sourced |
| Online seller of "research use only" peptides | Vials shipped to consumers | Research-use-only chemical businesses, including peptides, are generally not eligible | An explanation of who buys and why, which is where the model struggles |
LegitScript decides each application, and "generally" is its word, not ours.
Why a research-use-only label doesn't solve the problem
Because the label says the product isn't for people, and a consumer site sells it to people. A "not for human consumption" notice on a vial that a consumer site markets for recovery or weight loss is, in our view, the mismatch an underwriter is paid to find. It doesn't take the seller outside the rules; it adds a question about whether the seller's own description of the business is true.
It also closes the certification route. LegitScript generally doesn't certify research-use-only chemical businesses, including peptide sellers, so the step LegitScript describes as part of card-not-present approval is generally not open to the model.
And it can't be fixed by re-labelling or re-applying. Visa §1.9.1.4 lets Visa permanently prohibit a merchant, or its principals, for signing a new merchant agreement under a new name to get around the rules. A business that changes its model should expect to disclose the old one.
What a prescribing peptide clinic should have ready
A file that shows a real clinical relationship and a known pharmacy behind every fill:
- Licenses for each prescriber, in each state where you see patients.
- A prescription for an identified patient behind each 503A-compounded fill.
- The pharmacy's name and license, and whether it is a 503A pharmacy or an FDA-registered 503B outsourcing facility.
- Your product list, with a dated note from your regulatory counsel on where each item stands.
- Marketing copy kept to what your pharmacy and counsel support, with no "FDA approved" shortcuts.
- Your LegitScript status, or your application, if your model is in its scope.
- Billing terms and the refund policy shown at checkout.
- A plan for patients on a prepaid plan if a product becomes unavailable.
LegitScript asks the businesses it certifies to tell it about new services and other changes; it makes sense to treat your processor the same way when your product list changes. What LegitScript reviews and charges is in LegitScript certification for telehealth, and the wider set of factors that raise or lower a telehealth company's risk rating is in is telehealth a high-risk business.
VyaPay makes its risk decisions in-house on its own processor, so your product list, and counsel's notes on it, go straight to the people making the underwriting call. Talk to us about your program.
Frequently asked questions
Is BPC-157 legal to compound now?
We don't make that call. Legal and trade reporting says FDA removed it from 503A Category 2 in April 2026, and that removal doesn't by itself make a substance eligible for compounding. Ask regulatory counsel and the pharmacy.
Did FDA move peptides back to Category 1?
HHS Secretary Kennedy said in February 2026 that about 14 of 19 Category 2 peptides would move back, according to reporting. That was an intent, not a rule, and we haven't confirmed what happened after the July 2026 advisory committee meeting.
Can a peptide clinic get LegitScript certification?
LegitScript's FAQ says telemedicine providers are generally eligible and research-use-only chemical businesses, including peptides, generally are not. LegitScript decides each application on its own facts.
Will a processor accept research-use-only peptide sales?
No processor can answer for another, but the model generally has no LegitScript route and describes its own product as not for people. In our view, that is a very difficult file to underwrite.
Sources
- Goodwin, Frier Levitt and Pharmacy Times, reporting on FDA's 503A Category 2 peptide changes and the July 2026 Pharmacy Compounding Advisory Committee meeting, April–June 2026
- Legal Information Institute, 21 U.S.C. 353a (FD&C Act section 503A)
- Legal Information Institute, 21 U.S.C. 353b (FD&C Act section 503B)
- LegitScript, Healthcare Certification FAQ, read November 2026
- Visa, Visa Core Rules and Visa Product and Service Rules, 24 October 2026 (sections 1.9.1.4 and 1.9.5.1)
